These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Molecular simulations reveal the impact of RAMP1 on ligand binding and dynamics of calcitonin gene-related peptide receptor (CGRPR) heterodimer. Aksoydan B; Durdagi S Comput Biol Med; 2022 Feb; 141():105130. PubMed ID: 34923287 [TBL] [Abstract][Full Text] [Related]
64. A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine. von Mentzer B; Russo AF; Zhang Z; Kuburas A; Killoran PM; D'Aloisio V; Nizic L; Capel V; Kendall DA; Coxon CR; Hutcheon GA J Pharm Pharmacol; 2020 Oct; 72(10):1352-1360. PubMed ID: 32588458 [TBL] [Abstract][Full Text] [Related]
65. The role of the brainstem in migraine: Potential brainstem effects of CGRP and CGRP receptor activation in animal models. Holland PR; Saengjaroentham C; Vila-Pueyo M Cephalalgia; 2019 Mar; 39(3):390-402. PubMed ID: 29411638 [TBL] [Abstract][Full Text] [Related]
66. Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine. Durham PL Headache; 2008 Sep; 48(8):1269-75. PubMed ID: 18808507 [TBL] [Abstract][Full Text] [Related]
67. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis. Tringali G; Navarra P Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157 [TBL] [Abstract][Full Text] [Related]
68. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. Dubowchik GM; Conway CM; Xin AW J Med Chem; 2020 Jul; 63(13):6600-6623. PubMed ID: 32058712 [TBL] [Abstract][Full Text] [Related]
69. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. Bigal ME; Walter S CNS Drugs; 2014 May; 28(5):389-99. PubMed ID: 24638916 [TBL] [Abstract][Full Text] [Related]
70. Receptor activity-modifying protein-dependent effects of mutations in the calcitonin receptor-like receptor: implications for adrenomedullin and calcitonin gene-related peptide pharmacology. Watkins HA; Walker CS; Ly KN; Bailey RJ; Barwell J; Poyner DR; Hay DL Br J Pharmacol; 2014 Feb; 171(3):772-88. PubMed ID: 24199627 [TBL] [Abstract][Full Text] [Related]
71. Fluorescent Analogues of Human α-Calcitonin Gene-Related Peptide with Potent Vasodilator Activity. Zhu J; Pedersen MD; Ahmed LS; Abdolalizadeh B; Grell AS; Berg JO; Thulstrup PW; Franzyk H; Edvinsson L; Sams A; Sheykhzade M; Hansen PR Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079247 [No Abstract] [Full Text] [Related]
72. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Summ O; Charbit AR; Andreou AP; Goadsby PJ Brain; 2010 Sep; 133(9):2540-8. PubMed ID: 20802202 [TBL] [Abstract][Full Text] [Related]
74. Mapping interaction sites within the N-terminus of the calcitonin gene-related peptide receptor; the role of residues 23-60 of the calcitonin receptor-like receptor. Barwell J; Miller PS; Donnelly D; Poyner DR Peptides; 2010 Jan; 31(1):170-6. PubMed ID: 19913063 [TBL] [Abstract][Full Text] [Related]
75. Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies. Labruijere S; Ibrahimi K; Chan KY; Maassenvandenbrink A Expert Opin Drug Discov; 2013 Nov; 8(11):1309-23. PubMed ID: 23962310 [TBL] [Abstract][Full Text] [Related]
76. Pharmacological characterization of novel alpha-Calcitonin Gene-Related Peptide (CGRP) receptor peptide antagonists that are selective for human CGRP receptors. Taylor CK; Smith DD; Hulce M; Abel PW J Pharmacol Exp Ther; 2006 Nov; 319(2):749-57. PubMed ID: 16873605 [TBL] [Abstract][Full Text] [Related]
77. Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. Eftekhari S; Edvinsson L BMC Neurosci; 2011 Nov; 12():112. PubMed ID: 22074408 [TBL] [Abstract][Full Text] [Related]
78. Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine. Crowley BM; Stump CA; Nguyen DN; Potteiger CM; McWherter MA; Paone DV; Quigley AG; Bruno JG; Cui D; Culberson JC; Danziger A; Fandozzi C; Gauvreau D; Kemmerer AL; Menzel K; Moore EL; Mosser SD; Reddy V; White RB; Salvatore CA; Kane SA; Bell IM; Selnick HG; Fraley ME; Burgey CS Bioorg Med Chem Lett; 2015 Nov; 25(21):4777-4781. PubMed ID: 26231160 [TBL] [Abstract][Full Text] [Related]
79. Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine. Messlinger K; Fischer MJ; Lennerz JK Keio J Med; 2011; 60(3):82-9. PubMed ID: 21979827 [TBL] [Abstract][Full Text] [Related]
80. Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Hendrikse ER; Bower RL; Hay DL; Walker CS Cephalalgia; 2019 Mar; 39(3):403-419. PubMed ID: 29566540 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]